teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 10 Projects Releases Packages Wiki Activity Actions 1

extract: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination #1240

Merged
leo merged 2 commits from extract/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination into main 2026-03-18 11:33:10 +00:00
Conversation 4 Commits 2 Files changed 4 +2 -2
2 changed files with 2 additions and 2 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files
Showing only changes of commit e24b69f4d4 - Show all commits

2
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -79,7 +79,7 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF
### Additional Evidence (extend)
*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.

2
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -67,7 +67,7 @@ Digital behavioral support may partially solve the persistence problem: UK study
### Additional Evidence (extend)
*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.